A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus

Phase 1

• Conditions: Closed Fractures of the Humerus; MedDRA version: 8.1Level: LLTClassification code 10017127Term: Fracture of humerus

• Registration Number: EUCTR2006-001916-54-FR
• Lead Sponsor: Wyeth Pharmaceuticals Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-11-30
• Study Completion: 2010-02-23
• Last Update Posted: 8 October 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

1. Subjects signed and dated IRB or IEC-approved informed consent form.
2. Skeletally mature and aged >= 18 years
3. Subjects with a either a closed proximal humeral fracture or a diaphyseal humerus fracture classified as:
- Proximal Humeral Fracture (NEER classification): nondisplaced, minimally displaced (<45° angluation and <1cm displaced), 2-Part, 3-Part or 4-Part
- Diaphyseal Humeral Fracture (OTA classification): Simple OTA 12-A- Wedge OTA 12-B or Complexe OTA 12-C
4. Treatment plan includes only conservative (non-operative) therapy within 48 hours of injury.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Open proximal or humeral shaft fractures.
2. Additional planned procedure(s) to stimulate fracture union following application of an initial immobilization device.
3. Shoulder dislocation at the time of injury.
4. Fractures located in the distal third of the humerus.
5. Concurrent fractures of the ipsilateral or contralateral upper extremity that would impede performance on a functional assessment.
6. Treatment initiated for osteoporosis within the past 16 weeks.
7. Any previous use of therapies that can be considered bone anabolic (parathyroid hormone, growth hormone, anabolic steroids or fluoride at bone therapeutic doses) within the past year.
8. Pathological fractures, except if due to postmenopausal or senile osteoporosis

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified